PRESS RELEASE published on 11/08/2024 at 07:00, 1 year 9 months ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
PRESS RELEASE published on 09/12/2024 at 13:09, 1 year 11 months ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 06/17/2024 at 07:05, 2 years 2 months ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
BRIEF published on 06/17/2024 at 07:05, 2 years 2 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 2 years 2 months ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 2 years 2 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 2 years 3 months ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
BRIEF published on 05/28/2024 at 07:05, 2 years 3 months ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
PRESS RELEASE published on 05/28/2024 at 07:00, 2 years 3 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 2 years 3 months ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
Published on 08/29/2026 at 05:15, 1 day 10 hours ago Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 1 day 12 hours ago BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 1 day 14 hours ago Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 1 day 14 hours ago Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 1 day 16 hours ago Guanajuato Silver Grants Stock Options to Officer
Published on 08/29/2026 at 04:05, 1 day 11 hours ago INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 1 day 19 hours ago Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 1 day 19 hours ago Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 1 day 20 hours ago Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 1 day 21 hours ago CPI Europe announces unaudited results for the first half of 2026
